Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.775 USD | +7.58% |
|
+7.93% | -87.98% |
Business Summary
Number of employees: 384
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 33 | 01/13/01 |
Josh Cohen
FOU | Founder | 32 | 01/13/01 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 01/21/01 |
Chief Tech/Sci/R&D Officer | 71 | 28/11 | |
Lindsey Allen
IRC | Investor Relations Contact | - | - |
Gina Mazzariello
LAW | General Counsel | 52 | 23/22/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 01/15/01 |
Kari Firestone
BRD | Director/Board Member | 68 | 16/23/16 |
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 29/21/29 |
Daphne Quimi
BRD | Director/Board Member | 58 | 29/21/29 |
Josh Cohen
FOU | Founder | 32 | 01/13/01 |
Justin Klee
FOU | Founder | 33 | 01/13/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,005,749 | 58,032,930 ( 85.34 %) | 0 | 85.34 % |
Company contact information
![address Amylyx Pharmaceuticals, Inc.(AMLX)](https://cdn.zonebourse.com/static/address/131408793.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.98% | 112M | |
+2.22% | 93.53B | |
-1.32% | 38.27B | |
-13.63% | 32.84B | |
+76.30% | 27.83B | |
-12.96% | 16.08B | |
+0.76% | 14.02B | |
-12.06% | 11.47B | |
+185.28% | 9.92B | |
-53.00% | 9.42B |
- Stock Market
- Equities
- AMLX Stock
- Company Amylyx Pharmaceuticals, Inc.